ArticleBritish journal of cancer2017
Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies.
Article in British journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer.BMC cancer · 2019Pooled it
- Young-onset signet ring cell colorectal adenocarcinoma: demographics, clinicopathological profile, and survival analysis.Proceedings (Baylor University. Medical Center) · 2026Article
- Prognostic value of PLN, LNR, and LODDS in advanced colorectal signet ring cell carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- A distinct form of colorectal cancer: signet ring cell carcinoma.Translational cancer research · 2026Article
- Signet-Ring Cell Colorectal Cancer and Signet-Ring Cell Component Colorectal Cancer: Do They Differ in Clinical Behavior?Journal of clinical medicine · 2026Article
- Clinicopathologic, genetic and immune cell infiltration analysis of colorectal signet ring cell carcinoma with comparison to conventional adenocarcinoma.Journal of the National Cancer Center · 2026Article
- Clinicopathological Features and Prognostic Impact of Colorectal Signet-Ring Cell Carcinoma: The Prognostic Impact of Metastatic Lymph Node Histology.Journal of the anus, rectum and colon · 2026Article
- Article
- Ulcerative colitis and colorectal cancer: Pathogenic insights and precision strategies for prevention and treatment.World journal of gastrointestinal oncology · 2025Review
- Current status of multiple markers in precision immunotherapy for colorectal cancer.Cancer biology & medicine · 2025Article
- Evaluation of blood MSI burden dynamics to trace immune checkpoint inhibitor therapy efficacy through the course of treatment.Scientific reports · 2024Observational
- Molecular characteristics of patients with colorectal signet-ring cell carcinoma with different ABO blood groups.Heliyon · 2024Article
- Inherited KDM6AOncogene · 2024Article
- Systematic review of risk factors, prognosis, and management of colorectal signet-ring cell carcinoma.World journal of gastrointestinal oncology · 2024Article
- Prognostic and predictive value of tumor deposits in advanced signet ring cell colorectal cancer: SEER database analysis and multicenter validation.World journal of surgical oncology · 2024Article
- Gastrointestinal signet ring cell malignancy: current advancement and future prospects.Investigational new drugs · 2023Review
- Signet Ring Cell Colorectal and Appendiceal Cancer: A Small Signet Ring Cell Component Is Also Associated with Poor Outcome.Cancers · 2023Article
- Microsatellite Instability: A Review of Molecular Epidemiology and Implications for Immune Checkpoint Inhibitor Therapy.Cancers · 2023Review
- Primary signet-ring cell carcinoma of the renal pelvis: An autopsy case.IJU case reports · 2022Article
- Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets.Oncogene · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundSignet ring cell colorectal cancer (SRCCa) has a bleak prognosis. Employing molecular pathology techniques we investigated the potential of precision medicine in this disease.
methodsUsing test (n=26) and validation (n=18) cohorts, analysis of mutations, DNA methylation and transcriptome was carried out. Microsatellite instability (MSI) status was established and immunohistochemistry (IHC) was used to test for adaptive immunity (CD3) and the immune checkpoint PDL1.
resultsDNA methylation data split the cohorts into hypermethylated (n=18, 41%) and hypomethylated groups (n=26, 59%). The hypermethylated group predominant in the proximal colon was enriched for CpG island methylator phenotype (CIMP), BRAF V600E mutation and MSI (P<0.001). These cases also had a high CD3
conclusionsOur data show that SRCCa phenotype comprises two distinct genotypes. The MSI
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.